Leading proxy advisory firms iss and glass lewis demonstrate strong support for zevra's transformation strategy

Glass lewis recommends a vote “for” zevra's three nominees both iss and glass lewis recommend shareholders do not vote “for” any of the mangless nominees zevra urges shareholders to vote on the white proxy card celebration, fla., april 17, 2023 (globe newswire) -- zevra therapeutics, inc. (nasdaqgs: zvra) (“zevra” or the “company” and formerly kempharm, inc.), a rare disease therapeutics company, today announced that leading proxy advisory firms institutional shareholder services (“iss”) and glass lewis & co. (“glass lewis”) have voiced their support for zevra's nominees and strategy and found that mangless' arguments and nominees were not compelling.
ZVRA Ratings Summary
ZVRA Quant Ranking